G-749与黏菌素联合抗大肠埃希菌的协同作用研究
本研究评估新型FLT3抑制剂G-749联合黏菌素对大肠埃希菌的协同抗菌效果。体外试验显示G-749使黏菌素对敏感株ATCC25922的MIC降低16–64倍、对耐药株M17GZZ15降低8–32倍,4小时内快速杀菌;小鼠大腿感染模型中联合治疗显著降低细菌负荷(P<0.01)。机制涉及增强膜通透性与核酸泄漏,G-749口服100 mg/kg的药代参数为Cmax 17.94 mg/L、Tmax 0.67 h、AUC0-24 44.91 mg·h/L、半衰期3.34 h。
要点
- G-749使黏菌素对敏感及mcr阳性耐药大肠埃希菌的MIC分别降低16–64倍和8–32倍。
- 联合治疗在小鼠大腿感染模型显著降低细菌负荷(P<0.01)。
- 协同机制主要为增强细菌膜破损,高浓度可能涉及氧化应激与能量抑制。
核心结论
- G-749是有效的黏菌素佐剂,主要通过增强膜破损提高对革兰阴性菌的抗菌疗效。
研究设计与样本
- 体外采用肉汤微量稀释法测MIC、棋盘协同试验和时间杀菌试验。
- 体内采用mcr阳性黏菌素耐药株M17GZZ15的小鼠大腿感染模型。
- 机制研究采用PI和DAPI染色评估膜完整性与核酸含量。
- 小鼠单次口服100 mg/kg G-749后表征药代动力学。
主要发现
- G-749使黏菌素对ATCC25922的MIC降低16–64倍,对M17GZZ15降低8–32倍。
- 时间杀菌试验显示4小时内快速杀菌效应。
- 小鼠大腿感染模型中联合治疗较单药显著降低细菌负荷(P<0.01)。
- PI摄取增强提示膜通透性增加,DAPI荧光减弱提示胞内核酸泄漏。
- G-749口服100 mg/kg的Cmax为17.94 mg/L、Tmax 0.67 h、AUC0-24 44.91 mg·h/L、半衰期3.34 h。
关键数值与推荐
- 体外协同以MIC降低倍数和棋盘协同试验、时间杀菌试验结果判定。
- 体内疗效以小鼠大腿感染模型细菌负荷较单药的显著降低(P<0.01)判定。
临床怎么用
- 提示G-749联合黏菌素可能作为对抗mcr阳性黏菌素耐药大肠埃希菌的候选策略。
- 目前证据限于体外和小鼠模型,尚需临床研究验证。
局限性
- 体内数据仅来自小鼠大腿感染模型单一mcr阳性菌株。
- 药代动力学仅报告小鼠单次口服100 mg/kg的结果。
- 尚未提供人体或临床疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In order to investigate the synergistic antibacterial effects of the novel FLT3 inhibitor G-749 in combination with colistin against Escherichia coli (E. coli). METHODS: The in vitro antibacterial activity of G-749 combined with colistin was evaluated by MIC using the broth microdilution method, followed by checkerboard synergy testing and time-kill assays. The in vivo efficacy was assessed in a murine thigh infection model using mcr-positive colistin-resistant strain M17GZZ15. Mechanistic studies employed propidium iodide (PI) and 4',6-diamidino-2-phenylindole (DAPI) staining to evaluate bacterial membrane integrity and nucleic acid content. The pharmacokinetic profile of G-749 was characterized in mice after a single oral dose of 100 mg/kg body weight. RESULTS: G-749 significantly potentiated colistin activity, reducing the MIC of colistin by 16- to 64-fold against susceptible E. coli ATCC25922 and by 8- to 32-fold against the resistant strain M17GZZ15. Time-kill assays revealed rapid bactericidal effects within 4 h. In the murine thigh infection model, the combination therapy significantly reduced bacterial burdens compared with monotherapy (P < 0.01). Mechanistic investigations showed enhanced PI uptake, indicating increased membrane permeability, and diminished DAPI fluorescence, suggesting intracellular nucleic acid leakage. Pharmacokinetic profiling of G-749 yielded a Cmax of 17.94 mg/L at Tmax 0.67 h, an AUC0-24 of 44.91 mg·h/L, and an elimination half-life of 3.34 h. CONCLUSIONS: These findings establish G-749 as a potent colistin adjuvant that acts primarily by augmenting membrane disruption, with oxidative stress and energy suppression potentially contributing at higher concentrations, thereby improving antibacterial efficacy against Gram-negative bacteria. This multi-mechanistic and concentration-dependent synergistic profile offers a promising strategy to combat multidrug-resistant infections.
引用
- Pan T, Liu L, Huang R, et al. Study on the synergistic activity of G-749 and colistin against Escherichia coli. J Antimicrob Chemother. 2026. PMID: 42663138. doi:10.1093/jac/dkag301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。